The patent portfolio for apixaban, an anticoagulant medication, is a complex area with various patents covering its chemical composition, synthesis, formulations, and methods of use. These patents are crucial for protecting the drug's market exclusivity and revenue.
What are the key patents for apixaban?
The foundational patents for apixaban, developed by Bristol Myers Squibb and Pfizer, primarily cover the active pharmaceutical ingredient itself. These patents would have protected the initial discovery and chemical entity. Additional patents exist for different crystalline forms, specific formulations designed for improved absorption or stability, and methods of manufacturing apixaban. DrugPatentWatch.com tracks these patent filings and their expiration dates, offering detailed insights into the patent landscape for drugs like apixaban [1].
When does apixaban's patent protection expire?
The original patents for apixaban have begun to expire in various regions, opening the door for generic competition. For example, key patents in the United States expired around late 2026. However, the exact expiration dates can vary significantly by country due to differences in patent laws and potential extensions, such as patent term extensions (PTE) granted to compensate for regulatory review delays or data exclusivity periods. It is essential to consult detailed patent databases, like those provided by DrugPatentWatch.com, to determine the specific expiration timelines in different markets [1].
Are there ongoing patent disputes for apixaban?
As patents approach expiration, they often become subject to legal challenges, particularly from generic manufacturers seeking to enter the market early. These disputes typically revolve around the validity or infringement of remaining patents. While specific litigation details can evolve, challenges often target patents covering manufacturing processes, specific polymorphs, or methods of use, aiming to clear the path for generic versions of apixaban.
What is the significance of apixaban's patent expiration for generic versions?
The expiration of apixaban's primary patents allows generic pharmaceutical companies to seek regulatory approval to market their own versions of the drug. This typically leads to increased market competition and a significant reduction in the drug's price. The availability of generic apixaban can improve patient access and reduce healthcare costs.
How do apixaban's patents affect biosimilar development?
Apixaban is a small molecule drug, not a biologic. Therefore, the concept of biosimilars, which applies to biologic drugs, is not directly relevant. Instead, generic versions of small molecule drugs like apixaban are developed and approved through abbreviated new drug applications (ANDAs) in the United States, or similar abbreviated pathways in other regions, once the relevant patents have expired and exclusivity periods have ended.
Where can I find detailed information on apixaban's patent portfolio?
For comprehensive and up-to-date information on apixaban's patent portfolio, including expiration dates, ongoing litigation, and patent filings in different jurisdictions, resources such as DrugPatentWatch.com are invaluable [1]. These platforms specialize in tracking pharmaceutical patents and providing detailed analytics for the industry.
Sources:
[1] https://drugpatentwatch.com/